Company Profile
Seroxo is a clinical-stage in vitro diagnostics (IVD) company pioneering the development and commercialisation of a transformative POC test for monitoring inflammatory disease. Seroxo’s proprietary LIT™, a 10-minute finger-prick blood test, is a patented breakthrough technology that assesses real-time, 3D neutrophil function with applications in sepsis, cancer, and emergency triage. In particular, LIT is being developed for rapid detection and monitoring of sepsis and for recurrence surveillance and metastasis detection in cancer. With clinical data from ten international clinical studies in over 600 patients, LIT promises to radically improve patient outcomes with a near-patient test that revolutionises patient management.
Approach to Healthcare
Seroxo has developed a new biomarker for inflammatory disease that our clinical partners have demonstrated to be superior to current biomarkers such as C-reactive protein (CRP) and procalcitonin (PCT) in terms of speed and responsiveness. This will have a significant clinical impact in areas such as sepsis diagnosis and monitoring and in cancer recurrence surveillance. Our novel assay will benefit patients by improving patient outcomes and will provide critical data to help clinicians make make informed decisions much sooner than is possible currently .
Impact of Products/Services on Healthcare:
The Leukocyte ImmunoTest™ (LIT™) will improve detection and monitoring of deadly (and costly) conditions like sepsis, saving lives and reducing healthcare costs for organisations like the NHS.
Innovation
This is a highly innovative technology which will revolutionise challenging areas of healthcare that currently cause significant morbidity and morality. We have patents for use in sepsis and monitoring cancer recurrence and will continue to patent key innovations.
Future Direction
We are looking for clinical partners to conduct pivotal clinical trials in the UK to enable Seroxo to get the necessary data to support MHRA regulatory approval for launch in the UK. We are also looking for investors to support this important area.